Transferrin-oligomers as potential carriers in anticancer drug delivery

Pharmaceutical Research

Volumn 21, Issue 11, 2004, Pages 1985-1992

  Lim, Ching Jou ^a   Shen, Wei Chiang ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anticancer drug carriers; Intracellular drug release; Methotrexate; TfR targeting; Transferrin aggregates

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE; DRUG CARRIER; ETHYLENE GLYCOL DERIVATIVE; IODINE 125; METHOTREXATE; OLIGOMER; TRANSFERRIN; TRANSFERRIN RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE; CELL SURFACE RECEPTOR; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; LEUPEPTIN; POLYMER;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DEGENERATION; CELL STRAIN MCF 7; CHO CELL; CROSS LINKING; DRUG ACTIVITY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOCYTOSIS; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; WILD TYPE; ANIMAL; CELL PROLIFERATION; CELL STRAIN CACO 2; CHEMISTRY; DRUG EFFECT; HAMSTER; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; INDICATORS AND REAGENTS; LEUPEPTINS; METHOTREXATE; POLYMERS; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 21644459862     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000048188.69785.94     Document Type: Article

References (42)

1. B. Rihova. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 29:273-289 (1998).
2. D. J. Yamashiro and F. R. Maxfield. Acidification of endocytic compartments and the intracellular pathways of ligands and receptors. J. Cell. Biochem. 26:231-246 (1984).
3. H. J. Geuze, J. W. Slot, G. J. Strous, J. Peppard, K. Von Figura, A. Hasilik, and A. L. Schwartz. Intracellular receptor sorting during endocytosis: comparative immunoelectron microscopy of multiple receptors in rat liver. Cell 37:195-204 (1984).
4. V. Raso and M. Basala. A highly cytotoxic human transferrinricin A chain conjugate used to select receptor-modified cells. J. Biol. Chem. 259:1143-1149 (1984).
5. T. Tanaka, Y. Kaneo, and M. Miyashita. Intracellular disposition and cytotoxicity of transferrin-mitomycin C conjugate in HL60 cells as a receptor-mediated drug targeting system. Biol. Pharm. Bull. 21:147-152 (1998).
6. M. Singh. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. 5:443-451 (1999).
7. Z. M. Qian, H. Li, H. Sun, and K. Ho. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54:561-587 (2002).
8. I. S. Trowbridge and M. Omary. Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc. Natl. Acad. Sci. USA 78:3039-3043 (1981).
9. I. S. Trowbridge and J. F. Collawn. Structural requirements for high efficiency endocytosis of the human transferrin receptor. J. Inorg. Biochem. 47:209-217 (1992).
10. N. Girones. E. Alverez, A. Seth, I. M. Lin, D. A. Latour, and R. J. Davis. Mutational analysis of the cytoplasmic tail of the human transferrin receptor. Identification of a sub-domain that is required for rapid endocytosis. J. Biol. Chem. 266:19006-19012 (1991).
11. C. Harding, J. Heuser, and P. Stahl. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97:329-339 (1983).
12. J. A. Grasso, M. Bruno, A. A. Yates, L. T. Wei, and P. M. Epstein. Calmodulin dependence of transferrin receptor recycling in rat reticulocytes. Biochem. J. 266:261-272 (1990).
13. E. Aulbert. Anemia in malignant tumor diseases. I. Tumor-induced loss of transferrin and its relation to tumor size and degree of malignancy in the rat model. Nuklearmedizin 28:193-200 (1989).
14. E. Aulbert. Anemia in malignant tumor diseases. II. Tumor-induced loss of transferrin as a cause of the development of anemia based on a rat model. Nuklearmedizin 28:247-254 (1989).
15. E. Aulbert, M. Jakob, and E. Kurschel. Anemia in malignant tumor diseases. V. The relation of tumor induced hypotransferrinemia and the degree of anemia. Onkologie 12:81-89 (1989).
16. E. Aulbert, M. Jakob, and E. Kurschel. Anemia in malignant tumor diseases. VI. Secondary siderosis caused by the shift of iron, unused for hemoglobin synthesis, into iron stores. Med. Klin. 84:421-428 (1989).
17. M. Weaver and D. W. Laske. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 65:3-13 (2003).
18. W. C. Shen and H. J. Ryser. Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells. Mol. Pharm. 16:614-622 (1979).
19. J. J. Fitzpatrick and M. C. Garnett. Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers. Anticancer Drug Des. 10:1-9 (1995).
20. B. I. Schweitzer, A. P. Dicker, and J. R. Bertino. Dihydrofolate reductase as a therapeutic target. FASEB J. 4:2441-2452 (1990).
21. V. Raso, C. Fehrmann, V. C. Solan, and A. Rosowsky. Monensin is obligatory for the cytotoxic action of a disulfide linked methotrexate-anti- transferrin receptor conjugate. Biochem. Biophys. Res. Commun. 150:104-110 (1998).
22. J. N. Myers, I. Tabas, N. L. Jones, and F. R. Maxfield. β-VLDL is sequestered in surface-connected tubules in mouse peritoneal macrophages. J. Cell Biol. 123:1389-1402 (1993).
23. I. Tabas, S. Lim, X. X. Xu, and F. R. Maxfield. Endocytosed β-VLDL and LDL are delivered to different intracellular vesicles in mouse peritoneal macrophages. J. Cell Biol. 111:929-940 (1990).
24. I. Mellman, H. Plunter, and P. Ukkonen. Internalization and rapid recycling of macrophage Fc receptors tagged with monovalent antireceptor antibody: possible role of prelysosomal compartment. J. Cell Biol. 98:1163-1169 (1984).
25. E. W. Marsh, P. L. Leopold, N. L. Jones, and F. R. Maxfield. Oligomerized transferrin receptors are selectively retained by a lumenal sorting signal in a long-lived endocytic recycling compartment. J. Cell Biol. 129:1509-1522 (1995).
26. D. Shah and W. C. Shen. Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J. Pharm. Sci. 85:1306-1311 (1996).
27. S. Sonoda and M. Schlamowitz. Studies of 1251 trace labeling of immunoglobulin G by chloramine-T. Immunochemistry 7:885-898 (1970).
28. P. N. Kulkarni, A. Huntley Blair, and T. I. Ghose. Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res. 41:2700-2706 (1981).
29. W. F. Flintoff, S. V. Davidson, and L. Siminovitch. Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells. Somatic Cell Genet. 2: 245-261 (1976).
30. M. Pinto, S. Robin-Leon, M. Kedinger, N. Triadou, E. Dussaux, B. Lacroix, P. Simon-Assmann, K. Haffen, K. Fogh, and A. Zweibaum. Enterocytic differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell. 47:323-330 (1983).
31. C. R. Hopkins and I. S. Trowbridge. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J. Cell Biol. 97:508-521 (1983).
32. E. Wagner, D. Curiel, and M. Cotton. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev. 14:113-135 (1994).
33. R. Ippoliti, P. Ginobbi, E. Lendaro, I. D'Agostino, D. Ombres, P. A. Benedetti, M. Brunori, and G. Citro. The effect of monensin and chloroquine on the endocytosis and toxicity of chimeric toxins. Cell Mol. Life Sci. 54:866-875 (1998).
34. G. C. Todd, M. N. Novilla, and L. C. Howard. Comparative toxicology of monensin sodium in laboratory animals. J. Anim. Sci. 58:1512-1517 (1984).
35. M. Atef, M. A. Shalaby, M. G. el-Sayed, S. el-Din, A. H. Youssef, and M. A. el-Sayed. Influence of monensin on fertility in rats. Clin. Exp. Pharmacol. Physiol. 13:113-121 (1986).
36. S. C. Van Ijzendoorn and D. Hoekstra. The subapical compartment: a novel sorting centre? Trends Cell Biol. 9:144-149 (1999).
37. S. C. Van Ijzendoorn, O. Maier, J. M. Van Der Wouden, and D. Hoekstra. The subapical compartment and its role in intracellular trafficking and cell polarity. J. Cell. Physiol. 184:151-160 (2000).
38. D. R. Sheff, E. A. Daro, M. Hull, and I. Mellman. The receptor recycling pathway contains two distinct population of early endosomes with different sorting functions. J. Cell Biol. 145:123-139 (1999).
39. L. Zaliauskiene, S. Kang, C. G. Brouillette, J. Lebowitz, R. B. Arani, and J. F. Collawn. Down-regulation of cell surface receptors is modulated by polar residues within the transmembrane domain. Mol. Biol. Cell 11:2643-2655 (2000).
40. A. M. Weissman, R. D. Klausner, K. Rao, and J. B. Harford. Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor. J. Cell Biol. 102:951-958 (1986).
41. C. Q. Xia, J. Wang, and W. C. Shen. Hypoglycemic effect of insulin-transferrin conjugate in Streptozocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 295:594-600 (2000).
42. M. Jelinkova, J. Strohalm, T. Etrych, K. Ulbrich, and B. Rihova. Starlike vs classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs. Pharm. Res. 20:1558-1564 (2003).